EDWARD N. MERCER, B.A.SC., M.D., F.R.C.P.(C); JOHN A. OSBORNE, B.SC., M.D.
This content is PDF only. Please click on the PDF icon to access.
Diphenylhydantoin sodium (Dilantin®) is being widely investigated for the treatment of cardiac arrhythmias. The drug appears to offer some advantages, particularly with regard to safety, over other forms of drug therapy. Nonetheless, its use carries certain hazards, some of which may not be widely appreciated. The range of therapeutic usefulness of the drug in heart disease is becoming established, and its mode of action, although not yet fully elucidated, is undergoing intensive investigation. The purpose of this paper is to present data from 6 years' clinical experience with diphenylhydantoin (DPH) in the treatment of cardiac arrhythmias, to review the reported
MERCER EN, OSBORNE JA. The Current Status of Diphenylhydantoin* in Heart Disease. Ann Intern Med. 1967;67:1084–1107. doi: https://doi.org/10.7326/0003-4819-67-5-1084
Download citation file:
Published: Ann Intern Med. 1967;67(5):1084-1107.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use